Premium
A potential competition bias in the detection of safety signals from spontaneous reporting databases
Author(s) -
Pariente Antoine,
Didailler Marie,
Avillach Paul,
MiremontSalamé Ghada,
FourrierReglat Annie,
Haramburu Françoise,
Moore Nicholas
Publication year - 2010
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2022
Subject(s) - medicine , database , pharmacoepidemiology , competition (biology) , reporting bias , medline , pharmacology , computer science , medical prescription , ecology , political science , law , biology
Abstract Purpose To study whether reports related to known drug‐event associations could hinder the detection of new signals by increasing the detection thresholds when using disporportionality analyses in spontaneous reporting (SR) databases. Methods The French SR database (2005–2006 data) was used to test this hypothesis for the following events: bleeding, headache, hepatitis, myalgia, myocardial infarction, stroke, and toxic epidermal necrolysis (TEN). For each of these, using the Proportional Reporting Ratio (PRR) and the Reporting Odds Ratio (ROR), the number of cases needed to trigger a signal out of 50, 100, and 200 reports for a hypothetical newly introduced drug were computed before and after removing from the database reports involving drugs known to be associated with the event. Results For bleeding and stroke, removing potentially competitive data resulted in a decrease of the number of cases needed to trigger a signal for a newly introduced drug for both PRR and ROR (e.g., from 9 to 4, and 5 to 3 cases out of 50 reports for bleeding and stroke, respectively using the PRR). They were not or only slightly modified for the other studied events. Conclusions Removing reports related to known drug‐event associations could increase the sensitivity of signal detection in SR databases. This should be considered when using SR databases for signal detection as it could result in earlier identification of new drug‐event associations. Copyright © 2010 John Wiley & Sons, Ltd.